These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 15809486

  • 1. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ.
    J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
    [Abstract] [Full Text] [Related]

  • 2. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH.
    J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
    [Abstract] [Full Text] [Related]

  • 3. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
    Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):1192-8. PubMed ID: 16965873
    [Abstract] [Full Text] [Related]

  • 4. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW, Bijster M, Krenning EP, De Jong M.
    J Nucl Med; 2004 Jul 15; 45(7):1260-9. PubMed ID: 15235075
    [Abstract] [Full Text] [Related]

  • 5. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ.
    J Nucl Med; 2000 May 15; 41(5):952-8. PubMed ID: 10809213
    [Abstract] [Full Text] [Related]

  • 6. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA, White JD, Paik CH, Raubitschek A, Le N, Rotman M, Brechbiel MW, Gansow OA, Top LE, Perentesis P, Reynolds JC, Nelson DL, Waldmann TA.
    J Nucl Med; 1999 Feb 15; 40(2):268-76. PubMed ID: 10025834
    [Abstract] [Full Text] [Related]

  • 7. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
    Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7195s-7200s. PubMed ID: 16203821
    [Abstract] [Full Text] [Related]

  • 8. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.
    J Nucl Med; 2005 Apr 01; 46(4):642-51. PubMed ID: 15809487
    [Abstract] [Full Text] [Related]

  • 9. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH, Gao DW, Feng J, He J, Seo Y, Tedesco J, Wolodzko JG, Hasegawa BH, Franc BL.
    Mol Imaging Biol; 2009 Apr 01; 11(3):159-66. PubMed ID: 19034582
    [Abstract] [Full Text] [Related]

  • 10. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, Meares CF, Yuan A, Welborn JL, Denardo GL.
    Anticancer Res; 1997 Apr 01; 17(3B):1735-44. PubMed ID: 9179227
    [Abstract] [Full Text] [Related]

  • 11. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.
    J Nucl Med; 2003 Dec 01; 44(12):2000-18. PubMed ID: 14660727
    [Abstract] [Full Text] [Related]

  • 12. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
    Giblin MF, Sieckman GL, Shelton TD, Hoffman TJ, Forte LR, Volkert WA.
    Nucl Med Biol; 2006 May 01; 33(4):481-8. PubMed ID: 16720239
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma.
    Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR, Frincke JM, Lollo CP, Larson SM, Carrasquillo JA.
    Clin Cancer Res; 1998 Nov 01; 4(11):2691-700. PubMed ID: 9829731
    [Abstract] [Full Text] [Related]

  • 16. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM.
    J Nucl Med; 1998 Mar 01; 39(3):476-84. PubMed ID: 9529295
    [Abstract] [Full Text] [Related]

  • 17. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
    Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ.
    J Clin Oncol; 2005 Jul 20; 23(21):4591-601. PubMed ID: 15837970
    [Abstract] [Full Text] [Related]

  • 18. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, Goldenberg DM.
    J Nucl Med; 2005 Apr 20; 46(4):620-33. PubMed ID: 15809485
    [Abstract] [Full Text] [Related]

  • 19. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
    Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, Scher HI, Larson SM, Divgi CR.
    J Nucl Med; 2008 Jul 20; 49(7):1066-74. PubMed ID: 18552139
    [Abstract] [Full Text] [Related]

  • 20. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
    DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako Q, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, DeNardo SJ.
    Clin Cancer Res; 1998 Oct 20; 4(10):2483-90. PubMed ID: 9796981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.